Transcription profiling of human acute myeloid leukemia samples - a two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib

ABSTRACT: Currently there is no method available to predict response to farnesyltransferase inhibitors (FTI). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib, in older adults with previously untreated acute myeloid leukemia (AML). The RASGRP1:APTX gene expression ratio was found to predict response to tipifarnib with the greatest accuracy. This two-gene ratio was validated by quantitative PCR (QPCR) in the newly diagnosed AML cohort. We further demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a negative predictive value (NPV) and positive predictive value (PPV) of 92% and 28%, respectively (odds ratio of 4.4). The classifier also predicted f

ORGANISM(S): Homo sapiens

SUBMITTER: Jack Yu 

PROVIDER: E-GEOD-8970 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress